DelveInsight’s, “Follicular Lymphoma Pipeline Insight 2024” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Follicular Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Follicular Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Follicular Lymphoma Pipeline. Dive into DelveInsight’s comprehensive report today! @ Follicular Lymphoma Pipeline Outlook

Key Takeaways from the Follicular Lymphoma Pipeline Report

• July 2024:- Epizyme, Inc– A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma. Stage 1 is a safety run-in phase, was designed to evaluate the safety of the combination of tazemetostat and R2, as well as to establish the RP3D for Stage 2, which is now completed.
• July 2024:- Novartis Pharmaceuticals– A Randomized, Open-label, Multi-center Phase III Trial Comparing Tisagenlecleucel to Standard of Care in Adult Participants With Relapsed or Refractory Follicular Lymphoma (FL). This trial will compare tisagenlecleucel to standard of care in adult participants with relapsed or refractory (r/r) follicular lymphoma.
• July 2024:- M.D. Anderson Cancer Center– Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma. To determine the efficacy of obinutuzumab in combination with CC-99282 as determined by complete response (CR) rate after six cycles of combination treatment for patients with previously untreated, high tumor burden follicular lymphoma (FL).
• DelveInsight’s Follicular Lymphoma Pipeline report depicts a robust space with 45+ active players working to develop 50+ pipeline therapies for Follicular Lymphoma treatment.
• The leading Follicular Lymphoma Companies such as Mab Works, AstraZeneca, ADC Therapeutics, Xynomic Pharmaceuticals, AbbVie, Nurix, InnoCare Pharma, LTZ Therapeutics, Hutchmed, Regeneron Pharmaceuticals, Pfizer, InnoCare Pharma, TriSalus Life Sciences, BeiGene, and others.
• Promising Follicular Lymphoma Therapies such as Golcadomide, Obinutuzumab, CC-99282, Epcoritamab, Prednisone, Odronextamab, and others.

Stay ahead with the most recent pipeline outlook for Follicular Lymphoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Follicular Lymphoma Approved Drugs

Follicular Lymphoma Emerging Drugs Profile

• Mil62: Mab Works

MIL62 is a third-generation anti-CD20 antibody with a unique competitive position. MIL62 is the first domestically developed third-generation anti-CD20 antibody entering Phase III registration trial in China. MIL62 is self-developed by leveraging our ADCC-enhanced antibody platform. In in vitro and in vivo studies, MIL62 demonstrates stronger ADCC and anti-tumor activities than rituximab (first-generation anti-CD20 antibodies) and obinutuzumab (other third-generation anti-CD20 antibody). The company is implementing critical clinical development strategies to first pursue marketing approval from the NMPA for the treatment of relapsed and/or refractory FL patients and DLBCL patients. At the same time, MIL62 is being developed for previously untreated FL and DLBCL patients (a significantly larger patient population) by demonstrating clinical superiority over rituximab.

• Loncastuximab tesirine: ADC Therapeutics

Loncastuximab tesirine-lpyl is an ADC composed of a humanized monoclonal antibody that binds to human CD19 and is conjugated through a linker to a PBD–dimer toxin. Once bound to a CD19-expressing cell, loncastuximab tesirine-lpyl is internalized into the cell, where enzymes release the PBD-based warhead. The warhead is designed to bind irreversibly to DNA to create highly potent interstrand cross-links that block DNA strand separation, thus disrupting essential DNA metabolic processes such as replication. This ultimately results in cell death. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Follicular Lymphoma.

• NX-2127: Nurix

NX-2127 is an oral small molecule degrader of BTK and cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos). Cereblon immunomodulatory drugs that induce degradation IKZF1 and IKZF3 such as lenalidomide and pomalidomide are FDA approved for a variety of hematologic malignancies including multiple myeloma, follicular lymphoma, and mantle cell lymphoma. We hypothesize that the combination of BTK degradation and cereblon immunomodulatory activity will have enhanced therapeutic benefit in patients suffering from a variety of B-cell malignancies. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Follicular Lymphoma.

• ABBV-319: AbbVie

ABBV-319 is a novel oncology first-in-class steroid-based antibody-drug conjugate (ADC) targeting CD19 that is anticipated to have robust single-agent activity and provide significant clinical benefit as combination therapy in various B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). The mechanism of action involves the ADC binding to CD19 on the surface of B-cell cancer cells, followed by internalization into the cells through receptor-mediated endocytosis. Once inside, the linker component of the ADC is cleaved, releasing the cytotoxic drug payload, which then targets and kills the cancer cells. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Follicular Lymphoma.

Explore groundbreaking therapies and clinical trials in the Follicular Lymphoma Pipeline. Access DelveInsight’s detailed report now! @ Follicular Lymphoma Treatment Drugs

Follicular Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Follicular Lymphoma Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Unveil the future of Follicular Lymphoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Follicular Lymphoma Market Drivers and Barriers

Scope of the Follicular Lymphoma Pipeline Report

• Coverage- Global
• Follicular Lymphoma Companies- Mab Works, AstraZeneca, ADC Therapeutics, Xynomic Pharmaceuticals, AbbVie, Nurix, InnoCare Pharma, LTZ Therapeutics, Hutchmed, Regeneron Pharmaceuticals, Pfizer, InnoCare Pharma, TriSalus Life Sciences, BeiGene, and others.
• Follicular Lymphoma Therapies- Golcadomide, Obinutuzumab, CC-99282, Epcoritamab, Prednisone, Odronextamab, and others.
• Follicular Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Follicular Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Follicular Lymphoma Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Follicular Lymphoma Companies, Key Products and Unmet Needs

Table of Content

1. Introduction
2. Executive Summary
3. Follicular Lymphoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Follicular Lymphoma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Mil62: Mab Works
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Loncastuximab tesirine: ADC Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. NX-2127: Nurix
15. Mid Stage Products (Phase II)
16. Preclinical Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Follicular Lymphoma – Collaborations Assessment- Licensing / Partnering / Funding
21. Follicular Lymphoma – Unmet Needs
22. Follicular Lymphoma – Market Drivers and Barriers
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/